| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| ln Vivo |
In rats and guinea pigs with epileptic seizures, procyclidine hydrochloride (subcutaneous injection, 0.3-6.0 mg/kg) combined with physostigmine (PhS) increases protection in a dose-dependent manner and completely prevents somanvirus infection[1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat, Dunkin-Hartley male guinea pig [1]
Doses: 0.3-6.0 mg/kg Route of Administration: subcutaneous injection; Experimental Results: The protective effect was enhanced at doses of 0.3, 1.0, 3.0 or 6.0 mg /kg, the protective effects in rats were increased by 1.92, 2.24, 3.95 and 5.07 times respectively, and the protective effects in guinea pigs were increased by 3.00, 3.25, 4.50 and 4.70 times respectively. Protects the integrity of the brain's nervous system and prevents Soman-induced severe brain damage to the hippocampus, cortex, amygdala and thalamus. |
| References |
|
| Additional Infomation |
Procyclidine hydrochloride is the hydrochloride salt form of propcycline and possesses anticholinergic properties. Procyclidine hydrochloride competitively binds to striatal cholinergic receptors, thereby reducing acetylcholine activity and ultimately decreasing the frequency and severity of kinesia, rigidity, and tremor associated with uncontrollable body movements. Furthermore, this drug may block the reuptake of dopamine at nerve endings, thereby increasing dopamine activity. Procyclidine is a muscarinic receptor antagonist that can cross the blood-brain barrier and is used to treat drug-induced extrapyramidal disorders and Parkinson's disease.
|
| Molecular Formula |
C19H30CLNO
|
|---|---|
| Molecular Weight |
323.9
|
| Exact Mass |
323.202
|
| CAS # |
1508-76-5
|
| Related CAS # |
Procyclidine;77-37-2
|
| PubChem CID |
207841
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
433.5ºC at 760 mmHg
|
| Melting Point |
85.5 to 86.5ºC
|
| Flash Point |
205.7ºC
|
| Vapour Pressure |
2.76E-08mmHg at 25°C
|
| LogP |
4.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(C1=CC=CC=C1)(C2CCCCC2)CCN3CCCC3.[H]Cl
|
| InChi Key |
ZFSPFXJSEHCTTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H29NO.ClH/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20;/h1,3-4,9-10,18,21H,2,5-8,11-16H2;1H
|
| Chemical Name |
1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol;hydrochloride
|
| Synonyms |
Procyclidine Hydrochloride Tricyclamol Wellcome Brand of Procyclidine Hydrochloride Procyclidine HCl Tricyclamol hydrochloride (-)-Tricyclamol iodide C19H29NO.HCl Rosemont Brand of Procyclidine HydrochlorideProcyclidine Hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~154.37 mM)
H2O : ~5.56 mg/mL (~17.17 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (6.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0874 mL | 15.4369 mL | 30.8737 mL | |
| 5 mM | 0.6175 mL | 3.0874 mL | 6.1747 mL | |
| 10 mM | 0.3087 mL | 1.5437 mL | 3.0874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
